Ted St. Martin, CPA, MBA Chief Financial Officer
Mr. St. Martin joined Dart NeuroScience in January 2012, with the merger of Helicon Therapeutics, Inc., where he served as controller. Ted brings more than 15 years of leadership in the life science industry and has served numerous biotechnology and life science organizations with various activities, including mergers and acquisitions, initial public offerings and private equity financings. From September 2007 to October 2010, Mr. St. Martin served as controller for Phenomix Corporation, a clinical stage biopharmaceutical company developing a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. While at Phenomix, Mr. St. Martin was responsible for managing the overall accounting function, including financial reporting, internal controls, collaboration accounting and participated in filing the company's initial public offering documents in 2008. Prior to his tenure at Phenomix, Mr. St. Martin was the controller at GeneOhm Sciences, a molecular diagnostics company, where he participated in a Series C round of venture financing, the acquisition of Infectio Diagnostics, Inc., and the subsequent acquisition of GeneOhm in 2006 by Becton Dickinson for $255 million. Mr. St. Martin began his career as an auditor for Ernst & Young where he served both public and private companies. He received a B.S. in accounting from Purdue University, an executive MBA from San Diego State University and an executive Certificate in the Business of Life Sciences from the Kelly School of Business at Indiana University. He is a certified public accountant with the State of California and a member of the Association of Bioscience Financial Officers.